JGL completes EUR 53 million investment project

MachinesBusinessSouth-East European INDUSTRIAL Мarket - issue 4/2023 • 07.11.2023

JGL completes EUR 53 million investment project

Croatia’s pharmaceutical company JGL celebrated the completion of the EUR 53 million investment project INTEGRA, which featured the unveiling of new laboratories for research, development and quality control, a pilot plant and a sterile production line for drops and sprays set to increase production capacity by up to 60%.

The occasion was attended by a host of distinguished guests from the world of business and politics. JGL’s new robotic logistics and distribution centre with 17 500 pallet spaces in Rijeka’s Kukuljanovo business zone was also presented. Also part of the INTEGRA project was the construction of additional facilities to improve the working conditions of employees and guests in the Pharma Valley complex, such as a restaurant, new offices, a lecture hall, a multi-purpose meeting room and a new JGL Pharmacy Museum exhibit.

“With INTEGRA, we are significantly increasing our technological resources and capacities and creating preconditions for the further advancement of our key brands in the global health market. In the life of every company, certain pivotal decisions become imprinted, ushering in an entirely new dimension for both the present and the future. At JGL, we have always believed in our capacity for growth, dreaming of transforming from a small local laboratory and becoming an international pharmaceutical company that operates far beyond the borders of our country. Quietly, with unwavering determination and a wealth of passion and energy, we built this house of ours, alongside its international position. Today, with our 150 brands, 300 products and 650 variations, we are present in 60 markets across the globe. Exports make up 86% of our business income”, said Ivo Usmiani, President of the JGL Board of Directors.

The increase in research and development capacities and their integration with production and quality in one location will strengthen JGL’s position in the development and production of advanced, innovative products within three strategic therapeutic areas – flu and cold, ophthalmology and dermatology.